Stage II (N1) lung cancer.
As therapies evolve and mature, the authors predict that the next 20 years will see significant advances in the understanding of non-small-cell lung cancer (NSCLC), in molecular stratification of NSCLC, and significant improvement in survival and cure rates. This survival will be achieved through early detection and combined treatments using effective surgical interventions, improved radiotherapeutics, and especially significantly enhanced, rationally designed systemic therapies.
Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California, USA.
O
O
Choy
T
T
Jahan
M
M
Roach
L
L
You
D
D
Jablons
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy*; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging